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SUMMARY
Toxoplasmosis is frequently acquired through the oral route by the ingestion of cysts or oocysts of Toxoplasma gondii. Once 
ingested, the parasites penetrate the intestinal epithelial cells and rapidly disseminate to all organs in the host. During T. gondii infection, 
the intestinal microbiota plays an important role in stimulating a protective immune response against the parasite. In this sense the 
use of probiotics is worthy of note since they are live microorganisms that have beneficial effects on the host through stimulation 
of the immune response that can be important in the control of T. gondii proliferation and dissemination in the host. In the present 
study, the action of the probiotic Bifidobacterium animalis subsp. lactis was investigated in C57BL/6 mice infected with oocysts of 
ME49 strain of T. gondii. The probiotic had an immunomodulatory action, inducing CD19 lymphocyte proliferation and consequently 
increasing anti-T. gondii antibody level. Bifidobacterium animalis subsp. lactis provided protection in supplemented mice, compared 
to the control group. In addition, supplemented animals had milder inflammatory process in the small intestine, indicating that the 
probiotic protects the intestinal mucosa during infection with T. gondii. It was concluded that the probiotic B. animalis subsp. lactis 
induces humoral immune response capable of providing protection against T. gondii infection.
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INTRODUCTION
Toxoplasma gondii is the etiologic agent of toxoplasmosis, a 
protozoonosis of worldwide distribution, which has caused high 
morbidity and mortality rates, especially for immunosuppressed 
individuals, constituting a serious public health problem. This disease 
has two phases: in the acute phase, there is rapid proliferation of 
tachyzoites, which occasionally causes symptomatology; in the chronic 
phase, the parasites form cysts that may persist for the whole life of 
the host in tissues such as the eye, the muscles and the central nervous 
system1.
An effective immune response plays an important role in the 
resistance to the disease. However, the immunological mechanisms 
of resistance to T. gondii infection have not been fully elucidated. The 
hosts control T. gondii infection by inducing a potent immunity mediated 
by TCD4+ and TCD8+ cells, the secretion of cytokines such as tumor 
necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ) which are 
essential to control the parasite proliferation and dissemination2,3. In 
addition, the increased humoral immune response will lead to a higher 
production of anti- T. gondii IgG antibodies, and the high IgG levels plays 
an important role in the protection against T. gondii infection, reducing 
the level of infection by this parasite3-5.
The intestinal microbiota plays a key role in the development, 
maturation and modulation of the immune system during infections, 
and studies in this field have attracted much interest in the last years6. 
In C57BL/6 mice, bacteria of the intestinal microbiota stimulate the 
development of a protective T helper type 1 (Th1) immune response 
through toll-like receptors, providing resistance against T. gondii 
infection7.
For the host’s protection against pathogens, the intestinal microbiota can 
be therapeutically manipulated by means of the administration of several 
microorganism species, which are called probiotics8. The mechanisms of 
action of probiotics have been recently assessed in infections with protozoa 
such as Giardia duodenalis, Cryptosporidium parvum and Eimeria 
tenella9-11, and in infections with nematodes such as Toxocara canis and 
Strongyloides venezuelensis12,13, yielding promising results. 
Considering T. gondii infection, only two studies have shown the 
effects of probiotics. Mice vaccinated with T. gondii cytoskeleton 
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proteins using Lactobacillus casei as adjuvant, had a protective immune 
response and greater anti-T. gondii IgG production14. In a second study, 
immunosuppressed female Wistar rats supplemented with the probiotic 
Bifidobacterium animalis subsp. lactis were capable of synthesizing 
IFN-γ and survived after inoculation of T. gondii RH strain, whereas 
immunosuppressed rats that were not supplemented with the probiotic 
died five days after the parasite inoculation. These results demonstrate 
that the immunomodulatory activity of B. animalis subsp. lactis can be 
beneficial, especially in individuals infected with T. gondii15.
The aim of this study was to evaluate the immunomodulatory action 
of B. animalis subsp. lactis in T. gondii-infected mice by quantifying 
the populations of CD4+, CD8+ and CD19+ lymphocytes in Peyer’s 
patches and by determining the serum antibody level, in order to correlate 
the immunological profile of animals with protection against T. gondii 
infection.
MATERIAL AND METHODS
Probiotic: Bifidobacterium animalis subsp. lactis (BB-12®; Christian 
Hansen) was activated in culture medium De Man Rogosa Sharpe16 
(Oxoid Ltd., Basingstoke, UK), modified with 0.02% sodium carbonate 
and 0.01% calcium chloride hydrate, and supplemented with 0.05% 
L-cysteine hydrochloride. Following incubation at 37 °C for 24 hours, 
B. animalis subsp. lactis was resuspended in milk at 1.6 x 108 CFU/mL.
Animals: This experimental protocol was approved by the Research 
Ethics Committee of São Paulo Institute of Tropical Medicine, University 
of São Paulo (CPE-IMT 2011/125). Male isogenic C57BL/6 mice, 
weighing approximately 20 g, were purchased from the Animal Facility 
Center of the School of Medicine, University of São Paulo. The animals 
were kept in the Laboratory of Protozoology of the São Paulo Institute 
of Tropical Medicine, University of São Paulo, inside polypropylene 
boxes containing autoclaved pine shavings; they received commercial 
animal food Nuvital® (Nuvital Nutrientes S/A, Colombo, PR, Brazil) 
and water ad libitum. 
Oocyst production: Cats were infected with cysts of T. gondii ME49 
strain to allow oocyst formation. Each cat received by gavage 800 tissue 
cysts of T. gondii obtained from previously infected mice17. Cats were 
kept in individual cages and received water and animal food ad libitum. 
Oocyst production was assessed from the 1st day post-infection (PI) to 
the 20th day PI. Feces were daily collected from each animal for oocyst 
detection based on the Sheather’s method18. Every time oocysts were 
detected, feces were mixed at a proportion of 1:1 with 2.5% sulfuric acid 
and maintained at room temperature during five days for sporulation. The 
quantity of oocysts was determined in a Neubauer counting chamber19. 
Oocysts were stored at 4 °C. 
Experimental design: For the experiment, nine groups of C57BL/6 
mice containing eight animals each were used. Four groups of animals 
infected with T. gondii and four groups of non-infected animals (control 
groups) were daily supplemented with 0.1 mL of milk containing 1.6 x 107 
CFU of B. animalis subsp. lactis or with 0.1 mL milk only. In addition, 
one group of animals that were neither infected nor supplemented with 
the probiotic or milk was used as a control. Supplementation of animals 
started on day 0 and continued until day 45 of the experiment. On day 15 
of the experiment, mice were orally infected with 102 oocysts of T. gondii 
ME49 strain. The animals were euthanized in a CO2 chamber on the 21th 
day, i.e., seven days PI with T. gondii (acute phase of toxoplasmosis) 
or on the 45th day, i.e., 30 days PI with T. gondii (chronic phase of 
the disease). Blood samples were collected from the animals for the 
determination of anti-T. gondii antibodies. From each mouse, the brain 
and the intestine were removed for the search of cysts and determination 
of the lymphocytes populations.
T. gondii antigen preparation: Tachyzoites of T. gondii RH strain 
were harvested from the peritoneal cavity of previously infected mice 
by PBS washes; suspensions were filtered through a 5 µm polycarbonate 
filter, and centrifugation was used to recover parasites, which were 
counted and re-centrifuged. Pellets were suspended in ice-cold water 
at a parasite density of 107 tachyzoites/ mL and subjected to sonication 
until complete cell lysis20.
Detection of specific antibodies in the serum of mice: The ELISA 
technique was used to detect anti-T. gondii IgG levels and confirm the 
infection in the acute and chronic phases. A 96-well polystyrene plate was 
sensitized with 100 µL of T. gondii antigen diluted in 0.1M carbonate-
bicarbonate buffer (pH 9.5) and kept overnight in a humid chamber at 
4 °C. Then, the plate was washed five times with 0.02% PBS-Tween and 
blocked with PBSTL solution (PBS containing 0.05% Tween-20 and 
0.3% skimmed milk) during 1 hour in an oven at 37 °C. After blockage, 
100 µL of the serum from each animal, at 1/100 dilution, were added to 
each well, and the plate was incubated at 37 °C for 1 hour. Subsequently, 
the plate was washed five times with PBSTL and received 100 µL/ well 
of anti-mouse IgG conjugate at 1: 20,000 dilution (Sigma-Aldrich®, St. 
Louis, MO, USA), followed by incubation for 1 hour at 37 °C. Then, the 
plate was washed again five times with PBSTL. The reaction was revealed 
by adding 100 µL of OPD (O-phenylenediamine 1 mg/mL, 0.03% H2O2 
in 0.2M phosphate-citrate buffer, pH 5.0) for 30 minutes and interrupted 
by adding 50 µL of 4N HCL. Absorbance of each well was determined 
in an automatic microplate reader (Multiskan MS® Labsystems Vienna, 
USA) at 492 nm21.
Determination of lymphocytes populations in mice: Peyer’s plates 
were removed from mice infected with T. gondii and from control 
animals to determine the population of CD19+ lymphocytes, CD3+CD4+ 
lymphocytes and CD3+CD8+ lymphocytes by means of flow cytometry. 
This was obtained by dissociating the intestine of animals under a sterile 
laminar flow to remove the Peyer’s patches on RPMI 1640 culture 
medium (Sigma®). After centrifugation of isolated cells at 2.800 rpm for 
15 minutes (centrifuge Z36HK, Hermle Labortechnik®), supernatant was 
discarded and cells were re-suspended in 1 mL ISOTON®, counted in a 
Neubauer chamber and, finally, adjusted to a concentration of 106 cells/ 
mL. Then, the cells underwent surface labeling by using monoclonal 
antibodies for differentiation of lymphocyte populations: CD3 Pacific 
blue (BD Biosciences), CD4 Horizon V500 (BD Biosciences), CD8 
APC-Cy7 (BD Biosciences) and CD19 PE-Cy7 (BD Biosciences). The 
cells were then incubated for 30 minutes at 4 °C in the absence of light. 
After this incubation period, 300 µL of ISOTON® solution were added 
and the analysis was carried out in a flow cytometer (LSRFortessa BD). 
A total of 10.000 events were captured by using BD FACSDIVA software 
and analyzed by Flowjo X software.
Brain cyst research: After 30 days of infection, mice euthanized 
in the chronic phase of toxoplasmosis had their brain removed and 
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homogenized in 10 mL of sterile saline. Cysts were counted under a 
phase contrast microscope11. Infection was defined as the presence of 
cysts and the disease was expressed as the number of cysts/ brain for each 
challenged animal. Infection protection was defined as the proportion of 
non-infected challenged animals, while disease protection was considered 
as the percentage drop of cyst counts in the brains of animals after the 
challenge5.
Histological analysis: The intestine of infected animals and control 
groups were removed, fixed with 10% formaldehyde and embedded 
in paraffin. Then, 7-µm sections of the material were stained with 
hematoxylin-eosin and examined for inflammatory changes.
Statistical analysis: The obtained quantitative values such as the 
level of antibodies, number and percentage of immune cells and number 
of cysts were statistically assessed by analysis of variance (ANOVA), 
employing the statistical package GraphPad Prism 6® (GraphPad Prism 
software, Inc. San Diego, CA, USA). All comparisons were performed 
at 5% significance level.
RESULTS
Serum humoral immune response in mice: Anti-T. gondii IgG 
levels were determined by the ELISA technique in the serum of mice 
infected with T. gondii oocysts. Serum samples were collected from 
the animals at seven and 30 days PI. Specific IgG antibody production 
in the serum of mice is shown in Table 1. There was a greater increase 
in antibody levels and progression for animals supplemented with B. 
animalis subsp. lactis, compared to animals supplemented with milk 
alone (p < 0.01; p < 0.001, respectively).
CD4+, CD8+ and CD19+ lymphocyte populations in mice: The 
influence of B. animalis subsp. lactis supplementation in C57BL/6 
mice challenged with T. gondii oocysts was verified by labeling and 
quantifying immune cell populations by flow cytometry. The proportion 
of C19+ cells was greater in animals supplemented with B. animalis 
subsp. lactis in the chronic phase of toxoplasmosis, compared to 
control animals (p < 0.05). The proportion of CD4+ T cells was smaller 
in infected mice supplemented with probiotics, compared to infected 
animals supplemented with milk (p < 0.001). Regarding CD8+ T cells, 
there was a decrease in the population during the infection of animals 
supplemented with probiotics; however, there was no statistical difference 
among the evaluated groups (Fig. 1).
Action of probiotics in cystogenesis: To assess whether B. animalis 
subsp. lactis supplementation influences T. gondii cystogenesis process, 
Fig. 1 - Percentage of intestinal free cells during experimental toxoplasmosis in animals receiving B. animalis subsp. lactis or milk. (A) Lymphocytes total; (B) CD19+ lymphocytes; (C) CD4+ 
lymphocytes; (D) CD8+ lymphocytes. Bonferroni´s post-test after p < 0.05 in ANOVA assays of two individual experiments. (*) represents p < 0.05; (**) represents p < 0.01; (***) represents 
p < 0.001 in comparison with the adequate control group.
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cysts from the brain of animals infected with T. gondii strain ME49 and 
supplemented with probiotics or milk were counted. The number of brain 
cysts was smaller in the group supplemented with probiotics, compared to 
the group supplemented with milk (p < 0.05). In addition, the number of 
animals supplemented with probiotics that showed absence of brain cysts 
was greater when compared to those supplemented with milk (Table 1).
Probiotic attenuates the inflammatory process in the intestinal 
mucosa of mice: The epithelium of the small intestine of mice infected 
with T. gondii was intact although, inflammatory infiltrates were present. 
Nevertheless, the infiltrates were restricted to the intestinal villi of animals 
supplemented with B. animalis subsp. lactis (Fig. 2) whereas they were 
found in the villi and crypts of Lieberkühn in animals supplemented 
with milk (Fig. 3), indicating a more severe inflammatory process in 
the latter. Peyer’s patches were only found in the intestine of probiotic-
supplemented mice, evidencing lymphocyte proliferation (Fig. 2).
DISCUSSION
Lately, much attention has been drawn to probiotics for their 
potential therapeutic application against several diseases caused 
by parasites. However, much of the effects of these probiotic 
microorganisms on parasitic infections has not been fully elucidated. 
In the present study, the action of the probiotic B. animalis subsp. lactis 
on T. gondii infection was assessed in C57BL/6 mice. To verify whether 
the animals were infected after challenge with T. gondii oocysts, 
serum was collected from all the animals to determine anti-T. gondii 
IgG levels. All the animals inoculated with oocysts were seropositive 
to T. gondii. However, anti-T. gondii IgG production was greater in 
animals supplemented with B. animalis subsp. lactis, and these higher 
IgG levels were related to the larger numbers of CD19+ lymphocytes 
found in probiotic-supplemented animals, indicating that B. animalis 
subsp. lactis had an immunomodulatory action, and induced humoral 
immune response in infected mice.
Some probiotics have already been reported to induce protective 
humoral immune response, increasing specific IgG levels during 
infection with parasitic protozoa. Broiler chickens infected with Eimeria 
acervulina or Eimeria tenella and supplemented with the probiotic 
microorganisms Pediococcus acidilactici and Saccharomyces boulardii 
had higher levels of specific IgG against these protozoa, and a reduced 
the number of excreted Eimeria oocysts was also found22. The present 
study is the first report of increased IgG levels and CD19+ lymphocyte 
population induced by the immunomodulatory action of B. animalis 
subsp. lactis during T. gondii infection. 
A humoral immune response with anti-T. gondii IgG production has 
been considered necessary to protect mice against T. gondii infection. 
Azzouz et al.2 noted that immunized BALB/c mice had a great production 
of anti-T. gondii IgG, assuring their survival during infection with T. 
gondii RH strain. 
Table 1 
Quantitative data on infection and antibody production during experimental 
toxoplasmosis for animals receiving B. animalis subsp. lactis or milk
Infection Diet Brain Cysts Mean ± S.E.M.
Anti T. gondii IgG 
(ELISA O.D.)
Acute Milk ND 0.423 ± 0.047
Probiotic ND 1.218 ± 0.185**
Chronic Milk 65.00 ± 16.80 1.100 ± 0.093
Probiotic 30.00 ± 12.54* 3.227 ± 0.052***
T test significance; (*) represents p < 0.05; (**) represents p < 0.01; 
(***) represents p < 0.001
Fig. 2 - Histological images of the small intestine of C57BL/6 mice challenged with oocysts 
of T. gondii ME49 strain and supplemented with probiotic. (a) Intestine of animals in the acute 
phase of toxoplasmosis. Intact intestinal villi and presence of inflammatory infiltrate in the 
villi (HE x 100). (b) Intact villosities, inflammatory infiltrate in the villi and discrete edema in 
the intestinal mucosa of mice in the chronic phase of infection (HE x 200). (c) Peyer’s patches 
in the intestine of a mouse in the chronic phase of toxoplasmosis (arrowhead) (HE x 40).
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Protection against T. gondii infection can be either qualitative, 
i.e., can be determined based on the frequency of investigated animals 
showing absence of cysts in their brain, or quantitative, which can 
be evidenced by a decrease in the parasite load. In this experiment, 
quantitative protection was verified by counting the tissue cysts present 
in the brain of animals infected with T. gondii and supplemented 
with probiotics or milk. C57BL/6 mice challenged with T. gondii and 
supplemented with B. animalis subsp. lactis had a smaller number of 
cysts in the brains, compared to mice that did not receive the probiotic, 
indicating a less severe infection in comparison with the control animals 
(p < 0.05). Considering the qualitative protection, a larger number of 
animals supplemented with the probiotic did not have tissue cysts in 
their brains, compared to control animals. Therefore, quantitative and 
qualitative protection can be related to the humoral immune response 
induced by B. animalis subsp. lactis, since those animals showed higher 
anti-T. gondii IgG levels. 
The results of the present study corroborate those described by 
Zorgi et al.5, who observed that a humoral response with IgG production 
provided quantitative protection to immunized BALB/c and C57BL/6 
mice challenged with T. gondii ME49 strain. Other studies have shown 
similar conclusions since immunized mice challenged with T. gondii 
have produced cell and humoral immune responses with high IgG titers, 
resulting in reduced formation of brain cysts3,4.
In addition, B. animalis subsp lactis provided intestinal mucosa 
protection since probiotic-supplemented animals showed less severe 
inflammatory processes, compared to control animals (Fig. 2, Fig. 
3). Although the mechanism of action of probiotics in regulating 
inflammation has not been elucidated, they are believed to interact with 
immunocompetent cells regulating the production of pro-inflammatory 
cytokines23,24. In T. gondii infection, CD4+ lymphocytes play their 
protective role by synthesizing IFN-γ, which gives the host resistance 
to infection by this parasite; however, the development of a strong 
Th1-type response with a large number of CD4+ cells and excessive 
IFN-γ production is related to several intestinal inflammatory changes 
associated with the mice mortality27. The small number of CD4+ cells 
verified in this study can be related to a less severe inflammatory process 
observed in animals supplemented with the probiotic, but future studies 
must be carried out to elucidate the role of B. animalis subsp lactis in 
the regulation of inflammation during T. gondii infection.
CD8+ T cells are considered important in the protection against T. 
gondii due to their cytotoxic activity in cells infected with this parasite. 
There was a reduction in the number of CD8+ T cells in probiotic-
supplemented mice, but there was no statistical difference among the 
assessed groups, indicating that the probiotic did not influence the 
population of those cells.
In conclusion, B. animalis subsp. lactis has a immunomodulatory 
activity since it induced humoral immune response with B lymphocyte 
proliferation and increased anti-T. gondii IgG level in animals infected 
with T. gondii. This immune response provided quantitative and 
qualitative protection in mice with toxoplasmosis. B. animalis subsp. 
lactis has attenuated the inflammatory process, and protected the intestinal 
mucosa of mice during toxoplasmosis.
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